State Group Insurance Program Coverage of Standard Fertility Preservation Services :
Summary
HB 677 amends Florida’s state group insurance law to require the Department of Management Services to provide coverage, in certain state group health insurance plans, for medically necessary standard fertility retrieval and preservation services when cancer treatment may directly or indirectly cause iatrogenic infertility. The bill applies to policies issued on or after January 1, 2026, and covers retrieval and storage of sperm, oocytes, and related materials when consistent with nationally recognized clinical practice guidelines.
The coverage is limited in duration: storage and retrieval coverage expires three years after the procedure that created the risk of infertility or when the person is no longer covered under the state plan, whichever comes first. The bill also bars preauthorization for these services, while allowing plans to impose maximum benefit limits and standard deductible, copayment, and coinsurance requirements. It defines key terms such as iatrogenic infertility, nationally recognized clinical practice guidelines, and standard fertility retrieval and preservation services, and takes effect July 1, 2025.
Impact
The bill expands the benefits required under Florida’s state employee group health insurance program by adding fertility preservation coverage tied to medically necessary cancer treatment. It amends section 110.12303, Florida Statutes, and affects the Department of Management Services, state group health insurance plan administrators, and covered employees and dependents who face treatment-related infertility risk. The measure creates a new statutory mandate for coverage, while preserving some plan design flexibility through benefit caps and normal cost-sharing.
Sentiment
The available context shows no recorded committee transcript or vote history, so there is no documented debate to indicate broad support or opposition in the provided materials. Based on the bill’s substance, it appears to be a targeted health-benefit expansion focused on patients facing cancer treatment and fertility loss, which typically draws support as a medical access measure. No formal sentiment can be inferred beyond the enacted status of the bill.
Contention
The main policy issues embedded in the bill are the scope and cost of required coverage, the exclusion of preauthorization, and the limits placed on duration and benefit levels. Potential points of contention would likely involve state plan expenses, administrative controls, and how broadly fertility preservation should be covered for treatment-related infertility. The bill’s definitions and reliance on nationally recognized clinical guidelines may also matter to insurers and administrators because they determine which procedures qualify.